Linked Data API

Show Search Form

Search Results

176643
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Cancer Drugs Fund more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty’s Government why patients and patient groups are not allowed to appeal decisions of NHS England to exclude certain drugs from the approved list in the Cancer Drugs Fund. more like this
tabling member printed
Lord Hunt of Kings Heath more like this
uin HL4552 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-10more like thismore than 2015-02-10
answer text <p>NHS England’s Cancer Drugs Fund (CDF) Standard Operating Procedure (SOP) outlines that applications to include candidate drugs/indications for inclusion in the national CDF list can only be made directly for potential cohorts of patients by the pharmaceutical industry and/or clinicians.</p><p> </p><p> </p><p> </p><p>There are two different routes for applicants to challenge the decisions of the national Cancer Drugs Fund panel – either by making a complaint to the Chair of the panel and/or by requesting a formal review (often referred to as an ‘appeal’).</p><p> </p><p><strong> </strong></p><p> </p><p>The complaints process outlined within the CDF SOP, indicates that a complaint can be made by either the manufacturer or a clinician where there is dissatisfaction with the outcome (either inclusion or exclusion of a drug) in respect of the national CDF list. A complaint must be made by a written letter to the chair of the panel outlining the reasons for the complaint.</p><p> </p><p> </p><p> </p><p>A formal review, which is undertaken by NHS England’s Cancer and Blood Programme of Care Board, can only be requested by the original applicants to the CDF where the application has been unsuccessful.</p><p> </p><p> </p><p> </p><p>With regard to the decisions announced by NHS England on 12 January 2015, all complaints or requests for a formal review must be submitted by 9 February 2015.</p><p> </p><p> </p><p> </p><p>NHS England’s <a title="Standard Operating Procedures: The Cancer Drugs Fund - Opens in a new window (937kb)" href="http://www.england.nhs.uk/wp-content/uploads/2014/11/sop-cdf-1114.pdf" target="_blank">CDF Standard Operating Procedure document</a> is available at:</p><p> </p><p> </p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2014/11/sop-cdf-1114.pdf</p><p> </p><p> </p><p> </p><p>Clinicians will continue to be able to apply for individual patients to receive drugs not on the national CDF list on an exceptional basis.</p><p> </p><p> </p><p> </p><p>Patients have the right to make a complaint using the National Health Service complaints process and, under this process, complainants have 12 months in which to lodge their complaint. This is separate to the CDF complaints process referenced above, which can only be accessed by CDF applicants and clinicians. Details of the NHS complaints process can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplaints.aspx" target="_blank">www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplaints.aspx</a></p><p> </p>
answering member printed Earl Howe more like this
grouped question UIN HL4553 more like this
question first answered
less than 2015-02-10T15:48:48.61Zmore like thismore than 2015-02-10T15:48:48.61Z
answering member
2000
label Biography information for Earl Howe more like this
tabling member
2024
label Biography information for Lord Hunt of Kings Heath more like this
176644
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Cancer Drugs Fund more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty’s Government how patients' interests are able to be represented if a company chooses not to appeal decisions of NHS England to exclude certain drugs from the approved list in the Cancer Drugs Fund. more like this
tabling member printed
Lord Hunt of Kings Heath more like this
uin HL4553 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-10more like thismore than 2015-02-10
answer text <p>NHS England’s Cancer Drugs Fund (CDF) Standard Operating Procedure (SOP) outlines that applications to include candidate drugs/indications for inclusion in the national CDF list can only be made directly for potential cohorts of patients by the pharmaceutical industry and/or clinicians.</p><p> </p><p> </p><p> </p><p>There are two different routes for applicants to challenge the decisions of the national Cancer Drugs Fund panel – either by making a complaint to the Chair of the panel and/or by requesting a formal review (often referred to as an ‘appeal’).</p><p> </p><p><strong> </strong></p><p> </p><p>The complaints process outlined within the CDF SOP, indicates that a complaint can be made by either the manufacturer or a clinician where there is dissatisfaction with the outcome (either inclusion or exclusion of a drug) in respect of the national CDF list. A complaint must be made by a written letter to the chair of the panel outlining the reasons for the complaint.</p><p> </p><p> </p><p> </p><p>A formal review, which is undertaken by NHS England’s Cancer and Blood Programme of Care Board, can only be requested by the original applicants to the CDF where the application has been unsuccessful.</p><p> </p><p> </p><p> </p><p>With regard to the decisions announced by NHS England on 12 January 2015, all complaints or requests for a formal review must be submitted by 9 February 2015.</p><p> </p><p> </p><p> </p><p>NHS England’s <a title="Standard Operating Procedures: The Cancer Drugs Fund - Opens in a new window (937kb)" href="http://www.england.nhs.uk/wp-content/uploads/2014/11/sop-cdf-1114.pdf" target="_blank">CDF Standard Operating Procedure document</a> is available at:</p><p> </p><p> </p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2014/11/sop-cdf-1114.pdf</p><p> </p><p> </p><p> </p><p>Clinicians will continue to be able to apply for individual patients to receive drugs not on the national CDF list on an exceptional basis.</p><p> </p><p> </p><p> </p><p>Patients have the right to make a complaint using the National Health Service complaints process and, under this process, complainants have 12 months in which to lodge their complaint. This is separate to the CDF complaints process referenced above, which can only be accessed by CDF applicants and clinicians. Details of the NHS complaints process can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplaints.aspx" target="_blank">www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplaints.aspx</a></p><p> </p>
answering member printed Earl Howe more like this
grouped question UIN HL4552 more like this
question first answered
less than 2015-02-10T15:48:48.703Zmore like thismore than 2015-02-10T15:48:48.703Z
answering member
2000
label Biography information for Earl Howe more like this
tabling member
2024
label Biography information for Lord Hunt of Kings Heath more like this
176645
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Maternity Services more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty’s Government what steps they are taking to improve maternity and neonatal care in NHS hospitals. more like this
tabling member printed
Lord Taylor of Warwick more like this
uin HL4554 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-12more like thismore than 2015-02-12
answer text <p>Women should receive excellent maternity services that focus on the best outcomes for women and their babies and on women’s experience of care. For premature and sick newborn babies and their families, neonatal services should deliver the best evidence-based care to improve both life expectancy and quality of life for newborn babies.</p><p> </p><p> </p><p> </p><p>Maternity services feature prominently in the key objectives set out in the Mandate between the Government and NHS England, which states that women should be offered the greatest choice of providers and a named midwife who is responsible for ensuring she has personalised one-to-one care throughout pregnancy, childbirth and during the postnatal period, including additional support for those who have a health concern.</p><p> </p><p> </p><p> </p><p>To support these objectives the Government has taken steps to improve the size and capacity of the maternity workforce and to improve the quality of the environments in which women give birth and are cared for. There is now a record number of midwives working in the National Health Service, nearly 2,000 more since 2010, and a record 6,400 midwifery students currently in training.</p><p> </p><p> </p><p> </p><p>The number of midwifery-led units has increased from 87 units in 2007 to 152 units in 2013, giving more women increased choice of place of birth. 79% of women of childbearing age in England now live within a 30 minute drive of both a midwifery-led unit and an obstetric unit - up from 59% in 2007.</p><p> </p><p>In 2013 and 2014, the Government invested £35 million in capital which provided new equipment and facilities such as birthing pools, reclining chairs and beds that allow fathers to stay overnight, ensuite bathrooms, midwife-led units, complex needs suites for women with mental health or substance misuse problems and bereavement rooms to support families after a stillbirth or an early neonatal death.</p><p> </p><p> </p><p> </p><p>The Friends and Family Test in December showed that 96% of women would recommend their maternity service for antenatal care, 97% for their labour and birth care and 98% for their postnatal community care.</p><p> </p><p> </p><p> </p><p>We have raised awareness of the importance of good maternal mental health during pregnancy and the first year after birth. The Mandate between the Government and NHS England also includes a specific objective to reduce the incidence and impact of postnatal depression through earlier diagnosis, and better intervention and support.</p><p> </p><p>In England, the number of inpatient mother and baby units specialising in psychiatric care during the perinatal period increased from 10 units in 2010 to 17 units in 2014.</p><p> </p><p>Health Education England (HEE) will ensure that training in perinatal mental health is available so that specialist staff will be available to every birthing unit by 2017. HEE will work with the National College of Midwifery and the Royal College of Midwives to ensure that there is a core module focussing on perinatal mental health in the undergraduate training of all midwives.</p><p> </p><p>We have trained 400 perinatal mental health visitor champions who are supporting health visitors with the identification and management of anxiety, mild to moderate depression and other perinatal mental disorders and knowing when to refer on.</p><p> </p><p> </p><p> </p><p>The Department has also commissioned the National Perinatal Epidemiology Unit at Oxford University to develop a perinatal mental health indicator, which will help us to better identify and address gaps in our services. NHS England is developing a plan to support women with postnatal mental health problems by March 2015 which will share best practice and learning with the NHS.</p><p> </p><p> </p><p> </p><p>The Government has also made reducing stillbirth an improvement area for the NHS in the NHS Outcomes Framework. The stillbirth rate is falling – from 3,558 stillbirths in 2012 to 3,284 in 2013. The Department of Health is working with key partners on programmes aimed at reducing stillbirth and neonatal mortality by raising awareness of the known risk factors, identifying the currently known and unknown factors and causes associated with perinatal and infant mortality and facilitating the learning and sharing of good practice across the NHS.</p><p> </p><p> </p><p> </p><p>As a specialised service, responsibility for commissioning neonatal critical care rests with NHS England. In 2014, NHS England published service specifications for neonatal critical care services and Neonatal Critical Care Retrieval, which take account of the principles set out in the <em>Toolkit for High Quality Neonatal Services</em> (2009).</p><p> </p><p> </p><p> </p><p>It is for local hospital trusts and specialised commissioners to decide how best to use the guidance and the NICE quality standard for specialist neonatal care to improve babies’ chances of survival and minimise mortality associated with being born either premature or unwell. Trusts should provide a family-centred approach to care and improve the quality of care by working in partnership with other providers and commissioners through Operational Delivery Networks as part of the broader Maternity and Children’s Strategic Network.</p><p> </p>
answering member printed Earl Howe more like this
question first answered
less than 2015-02-12T15:12:47.89Zmore like thismore than 2015-02-12T15:12:47.89Z
answering member
2000
label Biography information for Earl Howe more like this
tabling member
1796
label Biography information for Lord Taylor of Warwick more like this
176646
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Accident and Emergency Departments more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty’s Government what steps they will take to reduce excessive waiting times for accident and emergency patients. more like this
tabling member printed
Lord Taylor of Warwick more like this
uin HL4555 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-05more like thismore than 2015-02-05
answer text <p>The Government has given the National Health Service a record £700 million of additional support to ensure urgent and emergency care services are sustainable year-round and ready for the pressures of winter. Local plans to spend this money provide for nearly 8,800 extra staff and almost 6,500 extra beds. The Government is also acting to ease the pressure on accident and emergency (A&amp;E) departments, by supporting faster discharge from hospitals. We have given ring-fenced grant totalling £37 million to councils, to help prevent delayed discharges.</p><p> </p><p> </p><p> </p><p>For the longer term NHS England’s urgent and emergency care review is looking at ways to improve the system, including easing pressures on A&amp;E departments.</p><p> </p> more like this
answering member printed Earl Howe more like this
question first answered
less than 2015-02-05T13:21:41.163Zmore like thismore than 2015-02-05T13:21:41.163Z
answering member
2000
label Biography information for Earl Howe more like this
tabling member
1796
label Biography information for Lord Taylor of Warwick more like this
176648
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading IVF more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty’s Government whether robust clinical trials are planned to take place for both pronuclear transfer and spindle-chromosomal complex transfer; and if not, why not. more like this
tabling member printed
Lord Morrow more like this
uin HL4557 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-12more like thismore than 2015-02-12
answer text <p>The provision of treatment services involving the use of the Maternal Spindle Transfer and Pronuclear Transfer mitochondrial donation techniques will not be provided as a clinical trial.</p><p> </p><p> </p><p> </p><p>Clinical trials are regulated by the Medicines for Human Use (Clinical Trials) Regulations 2004, which implements the Clinical Trials Directive 2001/20/EC. The Regulations do not cover treatment services.</p><p> </p><p> </p><p> </p><p>The Regulations define a clinical trial as:</p><p> </p><p> </p><p> </p><p>“clinical trial” means any investigation in human subjects, other than a non-interventional trial, intended—</p><p> </p><p>(a) to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal products,</p><p> </p><p>(b) to identify any adverse reactions to one or more such products, or</p><p> </p><p>(c) to study absorption, distribution, metabolism and excretion of one or more such products,</p><p> </p><p> </p><p> </p><p>with the object of ascertaining the safety or efficacy of those products;”.</p><p> </p><p> </p><p> </p><p>If the Draft Human Fertilisation and Embryology Authority (Mitochondrial Donation) Regulations 2015 are approved by Parliament, clinics wishing to offer this service will need to seek prior approval from the Human Fertilisation and Embryology Authority. Applications will be considered by the Authority on a case by case basis.</p><p> </p>
answering member printed Earl Howe more like this
grouped question UIN HL4558 more like this
question first answered
less than 2015-02-12T13:15:20.827Zmore like thismore than 2015-02-12T13:15:20.827Z
answering member
2000
label Biography information for Earl Howe more like this
tabling member
3795
label Biography information for Lord Morrow more like this
176649
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading IVF more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty’s Government what body will be responsible for overseeing clinical trials of pronuclear transfer and spindle-chromosomal complex transfer. more like this
tabling member printed
Lord Morrow more like this
uin HL4558 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-12more like thismore than 2015-02-12
answer text <p>The provision of treatment services involving the use of the Maternal Spindle Transfer and Pronuclear Transfer mitochondrial donation techniques will not be provided as a clinical trial.</p><p> </p><p> </p><p> </p><p>Clinical trials are regulated by the Medicines for Human Use (Clinical Trials) Regulations 2004, which implements the Clinical Trials Directive 2001/20/EC. The Regulations do not cover treatment services.</p><p> </p><p> </p><p> </p><p>The Regulations define a clinical trial as:</p><p> </p><p> </p><p> </p><p>“clinical trial” means any investigation in human subjects, other than a non-interventional trial, intended—</p><p> </p><p>(a) to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal products,</p><p> </p><p>(b) to identify any adverse reactions to one or more such products, or</p><p> </p><p>(c) to study absorption, distribution, metabolism and excretion of one or more such products,</p><p> </p><p> </p><p> </p><p>with the object of ascertaining the safety or efficacy of those products;”.</p><p> </p><p> </p><p> </p><p>If the Draft Human Fertilisation and Embryology Authority (Mitochondrial Donation) Regulations 2015 are approved by Parliament, clinics wishing to offer this service will need to seek prior approval from the Human Fertilisation and Embryology Authority. Applications will be considered by the Authority on a case by case basis.</p><p> </p>
answering member printed Earl Howe more like this
grouped question UIN HL4557 more like this
question first answered
less than 2015-02-12T13:15:21.013Zmore like thismore than 2015-02-12T13:15:21.013Z
answering member
2000
label Biography information for Earl Howe more like this
tabling member
3795
label Biography information for Lord Morrow more like this
176773
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading NHS: Standards more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what his assessment is of the contribution made by (a) the Care Quality Commission and (b) Monitor to (i) safeguarding and (ii) raising standards in healthcare. more like this
tabling member constituency Esher and Walton more like this
tabling member printed
Mr Dominic Raab more like this
uin 222655 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-03more like thismore than 2015-02-03
answer text <p>The Care Quality Commission (CQC) is the independent regulator of health and adult social care providers in England and has a key responsibility in the overall assurance of safety and quality of health and adult social care services.</p><p> </p><p> </p><p> </p><p>The CQC has provided the following information about its contribution to safeguarding:</p><p> </p><p> </p><p> </p><p>The CQC receives information that may relate to safeguarding from various sources, both professional and public. All concerns are relayed through the CQC’s National Customer Service Centre. The specialist team triage the information to identify whether this is information already known to a local authority or not, and if not CQC ensure an alert is made. All information relating to safeguarding concerns or alerts involving regulated services are sent directly to the appropriate inspection teams. Where the information indicates a serious concern, an unannounced inspection would be triggered. Depending on the outcome of that inspection, enforcement action could be taken against the provider.</p><p> </p><p> </p><p> </p><p>The CQC also use safeguarding information it collects to inform key publications. In the State of Care 2013-14 Report, the CQC used the information it holds on safety and safeguarding to highlight poor practice and signal where improvement is required from each of the sectors the CQC regulates.</p><p> </p><p> </p><p> </p><p>Monitor is the sector regulator for health services in England and its main duty is to protect and promote the interests of patients. Monitor is responsible for promoting the provision of health care services which is effective, efficient and which maintains or improves the quality of services.</p><p> </p><p> </p><p> </p><p>Monitor is also responsible for ensuring that foundation trusts (FTs) are run well so they can continue delivering good quality services for patients. To do this they work closely with the CQC, the quality and safety regulator. When the CQC establishes that an FT is failing to provide good quality care, Monitor can take action to address the problem.</p><p> </p><p> </p><p> </p><p>The licencing regime, introduced in the Health and Social Care Act is Monitor’s main tool for regulating providers of NHS services (unless exempt under section 83 of the Health and Social Care Act 2012) and gives it a means to carry out its responsibilities as sector regulator.</p><p> </p><p> </p><p> </p><p>FTs are expected to carry out external reviews of their governance every three years. Monitor provides guidance on this and sets out that the provision of safe, high quality, compassionate care should be a top priority for all FTs.</p><p> </p><p> </p><p> </p><p>FTs must also have regard to the NHS Constitution and, as autonomous organisations, are expected to adhere to regulations required of them by government.</p><p> </p><p> </p><p> </p><p>Monitor also meet with Ministers at the Department of Health on a quarterly basis to assess all aspects of their performance.</p><p> </p>
answering member constituency North Norfolk more like this
answering member printed Norman Lamb more like this
question first answered
less than 2015-02-03T15:36:44.403Zmore like thismore than 2015-02-03T15:36:44.403Z
answering member
1439
label Biography information for Norman Lamb more like this
tabling member
4007
label Biography information for Dominic Raab more like this
176774
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Cancer Drugs Fund more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, whether further discussions are planned between NHS England and the pharmaceutical industry before drugs are removed from the Cancer Drugs Fund list on 12 March 2015. more like this
tabling member constituency Mid Dorset and North Poole more like this
tabling member printed
Annette Brooke more like this
uin 222670 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-03more like thismore than 2015-02-03
answer text <p>NHS England has advised that A Cancer Drugs Fund Working Party has been established to review the future sustainability of the Fund and funding cancer drugs in general. The pharmaceutical industry is represented on this group.</p><p> </p><p> </p><p> </p><p>The removal of cancer drugs from the national Cancer Drugs Fund list is subject to a written review/complaint procedure and NHS England anticipates that a number of applications will be made under those processes.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2015-02-03T14:59:17.087Zmore like thismore than 2015-02-03T14:59:17.087Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1431
label Biography information for Annette Brooke more like this
176775
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Breast Cancer: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what estimate he has made of the number of breast cancer patients who will be affected by the removal of (a) eribulin, (b) lapatinib, and (c) everolimus from the Cancer Drugs Fund list on 12 March 2015. more like this
tabling member constituency Mid Dorset and North Poole more like this
tabling member printed
Annette Brooke more like this
uin 222671 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-03more like thismore than 2015-02-03
answer text <p>NHS England has advised that all patients currently being treated with eribulin, lapatinib or everolimus through the Cancer Drugs Fund (CDF) will continue with their treatment. Furthermore, clinicians will continue to be able to apply for individual patients to receive these drugs on an exceptional basis.</p><p> </p><p> </p><p> </p><p>Based on current applications received for these drugs, NHS England estimates that, on an annual basis, 1,730 patients treated with these drugs will be affected.</p><p> </p><p> </p><p> </p><p>NHS England has also advised that there are alternatives available for all these drugs within either baseline commissioning or the CDF. The purpose of NHS England’s recent review is to ensure that the very latest drugs are available to patients. The CDF has already helped over 60,000 patients.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2015-02-03T14:54:36.557Zmore like thismore than 2015-02-03T14:54:36.557Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1431
label Biography information for Annette Brooke more like this
176776
registered interest false more like this
date remove filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Meningitis: Vaccination more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, when he expects the Meningitis B vaccine to be made available on the NHS. more like this
tabling member constituency Bradford South more like this
tabling member printed
Mr Gerry Sutcliffe more like this
uin 222696 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2015-02-03more like thismore than 2015-02-03
answer text <p>The Department is continuing negotiations with the manufacturer to seek supply of the meningococcal B vaccine, Bexsero<sup>® </sup>at a cost-effective price as recommended by the Joint Committee on Vaccination and Imunisation. These negotiations will be completed as quickly as practicable.</p><p> </p> more like this
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
question first answered
less than 2015-02-03T15:05:12.58Zmore like thismore than 2015-02-03T15:05:12.58Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
403
label Biography information for Mr Gerry Sutcliffe more like this